US-based Amneal Pharmaceuticals, Inc. has launched its commercial operations in India. To helm its India commercial operations, Amneal has appointed Shyamakant Giri as Managing Director and President, India Business and Emerging Markets.  Giri has over two decades of experience leading business divisions and strategic operations of leading Indian and multinational organizations. In this new role, he will be responsible for Amneal's commercial expansion and growth in India, Africa, Gulf, CIS and South Asian markets.

Amneal Pharmaceuticals Inc. has a strong manufacturing and R&D footprint in India since 2008 with a focus on exports of key molecules and products thought its state-of-the-art world-class facilities across Ahmedabad, Dahej, Hyderabad and Vizag.  With the commencement of Amneal’s India commercial operations, the company aims to serve the unmet medical needs, and extend its industry-leading reputation for high quality products at affordable prices.

Delivering innovations in accessible medicines for patients and healthcare systems and building a strong foundation on honesty and integrity for the past 20+ years, the company has extended its portfolio from generics to specialty products, biosimilars and institutional injectables.